{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Tumor%2C+KRAS+Mutation&page=2", "query": { "condition": "Solid Tumor, KRAS Mutation", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Tumor%2C+KRAS+Mutation&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-11T02:44:54.421Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05002270", "title": "JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "NSCLC", "CRC" ], "interventions": [ { "name": "JAB-21822 (KRAS G12C inhibitor)", "type": "DRUG" }, { "name": "Cetuximab (EGFR inhibitor)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jacobio Pharmaceuticals Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2021-09-03", "completion_date": "2025-02-12", "has_results": false, "last_update_posted_date": "2026-01-13", "last_synced_at": "2026-06-11T02:44:54.421Z", "location_count": 4, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 1 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05002270" }, { "nct_id": "NCT06428500", "title": "QTX3046 in Patients With KRAS G12D Mutations", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "QTX3046", "type": "DRUG" }, { "name": "Cetuximab", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Quanta Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2024-05-30", "completion_date": "2027-07-01", "has_results": false, "last_update_posted_date": "2025-07-25", "last_synced_at": "2026-06-11T02:44:54.421Z", "location_count": 5, "location_summary": "Grand Rapids, Michigan • Durham, North Carolina • Houston, Texas + 2 more", "locations": [ { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT06428500" }, { "nct_id": "NCT07094204", "title": "A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Non-Small-Cell Lung Cancer", "Pancreatic Ductal Adenocarcinoma", "Colorectal Cancer" ], "interventions": [ { "name": "ASP5834", "type": "DRUG" }, { "name": "panitumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 364, "start_date": "2025-07-25", "completion_date": "2029-04-30", "has_results": false, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-06-11T02:44:54.421Z", "location_count": 11, "location_summary": "Santa Monica, California • Atlanta, Georgia • Jefferson, Louisiana + 8 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Jefferson", "state": "Louisiana" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07094204" }, { "nct_id": "NCT06364696", "title": "A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "ASP4396", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 175, "start_date": "2024-04-16", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-02-02", "last_synced_at": "2026-06-11T02:44:54.421Z", "location_count": 7, "location_summary": "Westwood, Kansas • Grand Rapids, Michigan • New York, New York + 4 more", "locations": [ { "city": "Westwood", "state": "Kansas" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Rochester", "state": "New York" }, { "city": "Irving", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06364696" }, { "nct_id": "NCT06385925", "title": "A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignant Neoplasm" ], "interventions": [ { "name": "TSN1611", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tyligand Pharmaceuticals (Suzhou) Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 440, "start_date": "2024-04-29", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-04-24", "last_synced_at": "2026-06-11T02:44:54.421Z", "location_count": 3, "location_summary": "Houston, Texas • San Antonio, Texas • Fairfax, Virginia", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06385925" }, { "nct_id": "NCT06179160", "title": "A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "INCB161734", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Retifanlimab", "type": "DRUG" }, { "name": "GEMNabP", "type": "DRUG" }, { "name": "mFOLFIRINOX", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "INCA33890", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 710, "start_date": "2024-01-04", "completion_date": "2027-01-01", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-06-11T02:44:54.421Z", "location_count": 15, "location_summary": "Phoenix, Arizona • Palo Alto, California • Santa Monica, California + 11 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06179160" }, { "nct_id": "NCT03965845", "title": "A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors", "NSCLC", "CRC", "KRAS Gene Mutation" ], "interventions": [ { "name": "Telaglenestat (CB-839)", "type": "DRUG" }, { "name": "Palbociclib Oral Capsule or Tablet [Ibrance]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Calithera Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2019-06-25", "completion_date": "2021-09-24", "has_results": false, "last_update_posted_date": "2022-09-19", "last_synced_at": "2026-06-11T02:44:54.421Z", "location_count": 10, "location_summary": "Santa Monica, California • Atlanta, Georgia • Chicago, Illinois + 6 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT03965845" }, { "nct_id": "NCT04853017", "title": "A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Minimal Residual Disease", "KRAS G12D", "KRAS G12R", "NRAS G12D", "NRAS G12R", "Pancreatic Ductal Adenocarcinoma", "Colorectal Cancer", "Non-small Cell Lung Cancer", "Ovarian Cancer", "Cholangiocarcinoma", "Bile Duct Cancer", "Gallbladder Carcinoma" ], "interventions": [ { "name": "ELI-002 2P", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Elicio Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2021-10-04", "completion_date": "2024-09-24", "has_results": true, "last_update_posted_date": "2025-09-05", "last_synced_at": "2026-06-11T02:44:54.421Z", "location_count": 10, "location_summary": "Duarte, California • Los Angeles, California • Aurora, Colorado + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04853017" }, { "nct_id": "NCT05786924", "title": "Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer", "Histiocytic Neoplasm", "Histiocytosis", "BRAF Gene Mutation", "BRAF V600E", "BRAF V600 Mutation", "BRAF Mutation-Related Tumors", "BRAF", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Lung Cancer", "Recurrent Lung Cancer", "Recurrent Lung Non-Small Cell Carcinoma", "NSCLC", "Solid Tumor", "Solid Carcinoma", "KRAS G12D", "KRAS G12V", "KRAS Mutation-Related Tumors", "NRAS Gene Mutation", "Thyroid Cancer", "Thyroid Carcinoma", "Colorectal Cancer", "Colorectal Carcinoma", "Recurrent Histiocytic and Dendritic Cell Neoplasm", "Brain Metastases", "Recurrent NSCLC", "KRAS G13C", "Acquired Resistance to KRAS G12C Inhibitor", "KRAS G12A", "KRAS G12F", "KRAS G12R", "KRAS G13D" ], "interventions": [ { "name": "S241656", "type": "DRUG" }, { "name": "FOLFOX6/FOLFOX7", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Panitumumab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Institut de Recherches Internationales Servier", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 554, "start_date": "2023-04-18", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-04-21", "last_synced_at": "2026-06-11T02:44:54.421Z", "location_count": 10, "location_summary": "Gilbert, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 7 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05786924" }, { "nct_id": "NCT03989115", "title": "Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "RMC-4630", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Drug: Osimertinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Revolution Medicines, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 113, "start_date": "2019-07-02", "completion_date": "2022-02-08", "has_results": true, "last_update_posted_date": "2023-06-26", "last_synced_at": "2026-06-11T02:44:54.421Z", "location_count": 21, "location_summary": "Scottsdale, Arizona • Duarte, California • Orange, California + 18 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03989115" } ] }